Naxodol (NSAID)

Quick links

Choose a section

Quick links to important sections

Advertisements

Naxodol (NSAID)

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Naxodol (NSAID)

Property Description
Active Ingredients Carisoprodol, Naproxen Sodium
Form Oral Solid Dosage (e.g., Tablet)
Pharmacological Class Skeletal Muscle Relaxant, Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use Relief of acute musculoskeletal discomfort
Origin Synthetic

What Type of Medicine is Naxodol (NSAID)?

Naxodol is a fixed-dose, synthetic combination medication classified simultaneously as a Skeletal Muscle Relaxant and a Nonsteroidal Anti-inflammatory Drug (NSAID). This product is intended for oral administration, typically supplied in a solid dosage form, and represents a dual-action approach to managing musculoskeletal discomfort. Naxodol is a brand-specific formulation distinguished by combining two distinct pharmacological components in a single tablet, which is often prescribed for adult patients. This combined format is clinically recognized for providing more comprehensive symptom management than either agent used alone.


Composition: Carisoprodol, Naproxen Sodium, and Pharmacological Class

Naxodol contains the muscle relaxant Carisoprodol and the anti-inflammatory agent Naproxen Sodium. The inclusion of Carisoprodol classifies the medicine as a carbamate derivative. Naproxen Sodium contributes the properties of an NSAID, which works by reducing the body's production of prostaglandins, key substances that cause pain, fever, and inflammation. The fixed composition is engineered to deliver both classes of therapeutic agents simultaneously, effectively targeting both the neurological component of spasm and the local inflammatory response.


General Purpose: Addressing Pain and Spasm Simultaneously

The general purpose of Naxodol is the short-term mitigation of the painful cycle associated with acute muscle strain or injury. The drug is designed for synergistic relief, leveraging the central action of the muscle relaxant to decrease involuntary muscle stiffness and combining this with the peripheral anti-inflammatory and analgesic effects of the NSAID component. For example, a typical use scenario involves relieving discomfort following an acute low back strain or a localized muscle injury. This dual approach directly targets both the tension and the inflammation, facilitating relief from acute, painful musculoskeletal conditions.

Regulatory References

  1. Naproxen (MedlinePlus Drug Information)
Advertisements

What side effects are possible with Naxodol (NSAID)?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Naxodol (Carisoprodol/Naproxen Sodium) as formally documented in government regulatory documents.

Official Adverse Reaction Scope

The most commonly documented adverse reactions relate to the Central Nervous System (CNS) and the gastrointestinal system. CNS effects, predominantly associated with the muscle relaxant component, include drowsiness, dizziness, and headache. Gastrointestinal effects, related to the NSAID component, often include dyspepsia, nausea, abdominal pain, and edema.

Adverse reactions are classified by the affected body system, which includes Nervous System Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, and Skin and Subcutaneous Tissue Disorders.

Classification Examples of Reactions
Common Drowsiness, dizziness, dyspepsia, nausea, headache
Uncommon/Rare Severe skin reactions, hepatic impairment, anaphylaxis

Serious Adverse Reaction Tiers

Regulatory documents emphasize the risk of serious adverse reactions, particularly those associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) component. These include life-threatening cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal ulceration, bleeding, and perforation of the stomach or intestines. Serious, though rare, idiosyncratic reactions have also been documented following the use of the muscle relaxant component.

Population and Exposure Safety Patterns

Population-specific safety considerations state that older adults are at a greater risk for serious gastrointestinal and cardiovascular adverse events. The NSAID component is also restricted from use late in pregnancy.

Regarding time-related patterns, the risk of serious cardiovascular events may occur early in treatment, and serious gastrointestinal events can occur at any time during the course of therapy. CNS depressant effects, such as drowsiness, may be more pronounced at the start of treatment. Safety constraints include contraindication for individuals with a history of allergic reactions to aspirin or other NSAIDs, or those with severe organ impairment.

Advertisements

Overdose and Emergency Response

Documented Overdose Manifestations

The official documentation defines overdose by the combined risks of the two active components, encompassing effects on the central nervous system (CNS) and major organ systems. Overdose may present with signs of CNS depression, including drowsiness, dizziness, confusion, and incoordination. Gastrointestinal manifestations such as nausea, vomiting, abdominal pain, and heartburn are also documented. Neurological findings that may be present include seizures, blurred vision, and muscular rigidity.

Serious Outcomes and Emergency Action

Severe overdose can progress to life-threatening outcomes, including respiratory depression, shock, and coma. The NSAID component carries the risk of serious complications like acute renal failure or severe Gastrointestinal bleeding and perforation. Death has been reported in cases of Carisoprodol overdose, often associated with multiple drug ingestions.

Immediate medical attention must be sought for any suspected overdose. Management is primarily symptomatic and supportive, as no specific antidote is known. Procedures such as the administration of activated charcoal and securing the airway for respiratory support are described as necessary regulatory measures. Elderly patients and those with existing renal or hepatic impairment are documented to be at greater risk for severe toxicity.

Advertisements

Therapeutic Uses of Naxodol (NSAID)

Naxodol is used in the short-term symptomatic management of specific musculoskeletal discomfort, and is relevant for easing symptoms that relate to both spasm and inflammation.

The muscle relaxant component is used to relieve discomfort caused by strains, sprains, and other muscle injuries. This dual-action medication is generally applied across domains where additional symptomatic support is needed in the management of acute painful musculoskeletal conditions, such as: muscle strains, acute sprains, and acute low back strain. It is relevant in clinical settings marked by heightened discomfort arising from recent, sudden tissue injury.


The combination may be relevant when symptoms cluster into patterns involving both involuntary muscle stiffness and painful muscle spasm. By assisting with the reduction of muscle tension, the medication may assist with managing the symptomatic patterns of pain and stiffness, which contributes to improved day-to-day comfort during difficult episodes. The medication is also considered relevant in conditions presenting with significant symptomatic burden, specifically addressing acute inflammatory pain and the associated local tenderness. It provides support that helps ease the overall symptom burden, offering a comprehensive symptomatic relief that helps patients cope more steadily.


Quick Fact: Relevant for Acute Musculoskeletal Symptoms Naxodol is commonly used to help with the relief of acute painful musculoskeletal conditions characterized by the combination of pain, muscle spasm, and inflammation.

Regulatory References

  1. NIH MedlinePlus overview on Carisoprodol
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Naxodol (Carisoprodol/Naproxen Sodium) is defined by regulatory agencies based on age, specific medical history, and pre-existing conditions.

Populations Allowed and Not Recommended

Use is established for adult patients (generally 16 years) for short-term management of acute musculoskeletal discomfort. However, the medicine is not recommended for pediatric patients less than 16 years of age, as safety and efficacy are not established. Use in patients aged 65 and older requires caution, particularly because the safety and efficacy of the Carisoprodol component are not established in this group. Use is also not recommended in patients with moderate to severe renal impairment.


Absolute Contraindications and Restrictions

Naxodol is contraindicated in patients with known hypersensitivity to aspirin, NSAIDs, or carbamates, as well as those with a history of acute intermittent porphyria or who are in the setting of coronary artery bypass graft (CABG) surgery. Regulatory guidelines advise to avoid use in cases of advanced renal disease, severe heart failure, and in women who are 30 weeks pregnant or later. Use is restricted in mid-pregnancy (20-30 weeks) and for breastfeeding mothers. Caution is mandatory for patients with a history of GI bleeding, CV risk factors, or substance use disorder.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Naxodol is structured by the distinct pharmacological properties of Carisoprodol and Naproxen Sodium. Co-administration of the Carisoprodol component with CYP2C19 inhibitors (such as Omeprazole) may result in increased systemic exposure of Carisoprodol. Conversely, CYP2C19 inducers (such as Rifampin or St. John's Wort) may lead to decreased exposure. A specific note in the label highlights that patients classified as CYP2C19 Poor Metabolizers also experience a significant increase in Carisoprodol exposure.

Pharmacodynamically, the sedative effects are additive when combined with alcohol or other CNS depressants (including Opioids and Benzodiazepines). The Naproxen component carries a documented risk of interaction with agents affecting hemostasis. Co-administration with anticoagulants (e.g., Warfarin), antiplatelet agents, SSRIs/SNRIs, or oral corticosteroids increases the risk of serious bleeding. Use with analgesic doses of Aspirin or other NSAIDs is not generally recommended.

Naproxen may also diminish the antihypertensive effect of drugs like ACE Inhibitors and ARBs, and can increase the serum concentration of Digoxin.

Advertisements

Mechanism of Action

Mechanism of Action: How Naxodol (NSAID) Works

Inhibition of Cyclooxygenase (COX) Enzymes

Naxodol exerts its primary mechanistic action by blocking the activity of the cyclooxygenase (COX-1 and COX-2) enzymes. This enzyme inhibition represents the initial, crucial step in the eicosanoid cascade, preventing the metabolic process that typically results in the creation of key inflammatory mediators.

Modulation of Prostaglandin Signaling Pathways

By inhibiting COX, Naxodol suppresses the synthesis of prostaglandins, lipid mediators derived from arachidonic acid. This action dampens excessive signaling within the humoral pathways that drive overactive physiological responses, modifying signal transduction within the targeted systems.

Physiological Consequence: Adjustment of Dysregulated Responses

The suppression of prostaglandin synthesis limits the downstream effects of excessive mediator activity, influencing the resulting physiological adjustments. This mechanistic domain operates within systems involving targeted pathway adjustment to modulate overactive or dysregulated physiological responses.

Advertisements

Dosage and Administration Information

Naxodol is an oral tablet prescribed for the short-term management of acute musculoskeletal discomfort. Its administration is strictly defined by regulatory guidance concerning route, frequency, duration, and patient-specific considerations. The medicine is prescribed for oral administration as a fixed-dose solid tablet.

The standard adult regimen involves taking one tablet of the fixed-dose combination. The dosing frequency is four times per day, typically defined as three times a day and once at bedtime.


Administration Specifics and Duration

Instruction Detail
Route: Oral route only (tablet).
Timing in relation to meals: Take with a full glass of water. May be administered with or after food.
Special Condition: Treatment duration must not exceed two or three weeks for acute use.

Population Considerations

Official guidelines for the components advise specific usage patterns for certain patient groups. For older adults, the use of the lowest effective dose is generally recommended. Similarly, patients with existing renal or hepatic impairment require caution, and the dosage should be initiated at the lowest effective amount. The medicine is not recommended for use in patients under 16 years of age.

The resulting protocol defines a clear procedural structure: administer the fixed-dose tablet orally, maintain the four-times-daily schedule, and adhere strictly to the two-to-three-week limit for acute treatment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Naxodol (Carisoprodol/Naproxen)

Evidence for Use in Acute Painful Musculoskeletal Conditions

The research base for Naxodol (Carisoprodol/Naproxen) is primarily built upon research exploring the components Carisoprodol and Naproxen. For the class of drugs intended to address musculoskeletal spasm and pain, the most common type of evidence is the short-term Randomized Controlled Trial (RCT). These trials was studied for patients experiencing recent, sudden-onset discomfort, such as an acute low back strain. Researchers examined patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level.

In these studies, findings describe patterns observed in the specific groups that were monitored over a short period. For the individual components, evidence describes patterns observed in the specific groups that was studied for addressing pain and spasm in this acute or disruptive episode setting. However, when research examined the approach of combining a muscle relaxant and an NSAID, results were mixed regarding whether the dual-component treatment was evaluated in comparison to taking a single ingredient alone. The research does not determine whether an individual will respond similarly.

Design of Key Studies: Focus on Symptoms and Function

Studies relevant in trials assessing short-term or episodic symptom patterns used standardized tools to measure the level of discomfort. Researchers applied in studies examining patient-reported experiences to measure changes in pain intensity through simple numerical rating scales. Furthermore, in research focusing on acute low back pain, outcomes related to functional limitations studies monitored the outcomes reflecting daily functioning or activity level as reported by the patient.

Duration of Evidence: Short-Term Trials and Follow-Up Periods

Research concerning the use of the component drugs in acute musculoskeletal conditions is characterized by follow-up durations that were limited. Most controlled studies research explored short-term symptom changes over periods lasting three to seven days. This short observation window is relevant in evidence describing how symptoms are measured during the expected recovery time for many acute injuries. Because the evidence base consists of short-term trials, long-term effects are not fully established.

Consistency and Limitations of the Evidence

Overall, the evidence quality varies across studies concerning the use of muscle relaxants and NSAIDs for acute musculoskeletal discomfort. Scientific reviews data show patterns related to symptom change over the short term for the drug classes. However, comparative evidence is lacking regarding this specific fixed-dose combination when directly examined against its individual components or alternative therapies. The limitations include sample sizes that were modest in some key studies, as well as follow-up durations that were limited to the acute phase. The existing research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Naxodol (NSAID) (FAQ)


Q: Is Naxodol considered a strong pain reliever?

Regulatory documents describe the Naproxen component of Naxodol as an NSAID (Nonsteroidal Anti-inflammatory Drug) approved for pain management. While it is indicated for acute painful conditions, official product information does not use terms like 'strong' to define its effect relative to all other types of pain relievers.


Q: How is Naxodol different from other common over-the-counter pain medications?

Naxodol is a fixed-dose combination product containing two types of active ingredients: a skeletal muscle relaxant and an NSAID (Naproxen Sodium). In contrast, most common over-the-counter pain relievers contain only one type of pain-relief agent. This combination is intended for the short-term relief of discomfort associated with acute muscle conditions.


Q: Why do doctors prescribe Naxodol instead of a different NSAID?

Naxodol combines an anti-inflammatory agent (the NSAID component) with a muscle relaxant (Carisoprodol). This approach includes components that target both pain/inflammation and the associated muscle spasm, according to the drug’s intended use for acute musculoskeletal conditions.


Q: Can Naxodol be used to treat headaches or migraines?

The official indication for Naxodol is specifically the relief of discomfort associated with acute, painful musculoskeletal conditions. Other uses, such as for headaches or migraines, are not listed within the product's primary approved indications according to regulatory documents.


Q: Does Naxodol work right away, or does it take time to feel the effects?

The effects of the muscle relaxant component (Carisoprodol) generally begin within about 30 minutes after taking the tablet. The NSAID component (Naproxen Sodium) typically reaches its highest level in the bloodstream in 1 to 2 hours after administration.


Q: What is the average duration of action for Naxodol?

The schedule defined in official labeling suggests a required frequency of administration. The Naproxen component has a longer half-life (how long it takes to clear the body), while the Carisoprodol component has a relatively short half-life of around 2 hours.


Q: Is Naxodol addictive or habit-forming?

The active ingredient Carisoprodol is classified as a Schedule IV controlled substance in the U.S. and has been subject to abuse, dependence, and withdrawal in post-marketing reports, particularly with prolonged use. Regulatory constraints specify that the product is intended for short-term use only.


Q: Are there any serious side effects of Naxodol that I should know about?

Official labeling highlights the risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and severe gastrointestinal bleeding, ulceration, or perforation. Rare but serious reactions like severe skin reactions (e.g., Stevens-Johnson Syndrome) and anaphylaxis have also been reported.


Q: Why do official documents mention heart-related risks with Naxodol?

Regulatory documents include a Boxed Warning that the NSAID component can cause an increase in the risk of serious cardiovascular thrombotic events, which include heart attack and stroke. This risk can happen early in treatment and may increase with longer use.


Q: Can Naxodol be taken with pain medications that are not NSAIDs?

Official documents specify that the sedative effects of the Carisoprodol component may be additive when combined with other Central Nervous System (CNS) depressants. The determination of whether to combine this drug with other pain medications requires evaluation by a healthcare provider.


Q: Does drinking alcohol affect the safety or effectiveness of Naxodol?

Official regulatory warnings state that patients should avoid the use of alcoholic beverages while using this medication. This is because the sedative effects of the muscle relaxant component and alcohol may be additive, potentially causing increased drowsiness or dizziness.


Q: What is the difference between prescription Naxodol and the over-the-counter version?

Naxodol is a prescription-only medication that combines two active ingredients. The Carisoprodol component is classified as a Schedule IV controlled substance, necessitating a prescription. While Naproxen Sodium is available over-the-counter alone, this specific dual combination is not available without a prescription.


Q: Why is Naxodol sometimes prescribed at different strengths?

This specific fixed-dose combination product is typically available in a single defined strength. However, the individual active ingredients, Carisoprodol and Naproxen Sodium, are separately available in multiple tablet strengths as single-ingredient products.


Q: Are there different brand names for the medicine Naxodol?

Naxodol is a brand name for this specific combination of Carisoprodol and Naproxen Sodium. Other brand names for fixed-dose combinations containing these same two active ingredients may exist in the market, along with generic versions of the combination.


Q: Do food or dairy products change how well Naxodol works?

Official labeling indicates that taking a meal, even a high-fat one, had no effect on how the Carisoprodol component is absorbed. The medication can therefore be administered with or without food.


Q: What are the signs of an allergic reaction to Naxodol?

Naxodol can cause severe allergic reactions (anaphylaxis). Signs of a reaction may include hives, swelling of the face, wheezing (asthma), or shock. Official documents specify that immediate emergency medical attention is necessary if an allergic reaction occurs.


Q: Can Naxodol affect my ability to drive or operate machinery?

Yes, due to the sedative properties of the muscle relaxant component, the medicine may impair the mental and/or physical abilities needed to perform hazardous tasks. Patients are cautioned about driving a motor vehicle or operating heavy machinery while taking it.


Q: Can Naxodol cause sensitivity to the sun?

The NSAID component (Naproxen) has been associated with photosensitivity (increased skin sensitivity to sunlight) in post-marketing reports. Official guidance suggests discontinuing the drug at the first sign of a rash or other hypersensitivity reaction.


Q: What should I do if I think Naxodol isn't working for my pain?

This medication is intended for a short duration (typically up to two or three weeks). If musculoskeletal symptoms persist after the maximum recommended duration of use, regulatory information indicates that further evaluation by a healthcare provider is appropriate.


Q: Can Naxodol cause changes in mood or sleep?

Yes, regulatory documents list Central Nervous System adverse reactions associated with the muscle relaxant component. These effects include reported changes such as insomnia (difficulty sleeping), agitation, irritability, and depressive reactions.


Q: What information do official sources provide about Naxodol and liver health?

The Naproxen component carries a warning for Hepatotoxicity (potential for liver injury). The label advises patients to be aware of the signs of liver toxicity and to discontinue the medication if abnormal liver tests persist or worsen, or if symptoms of liver disease develop.


Q: Is it possible to develop a tolerance to Naxodol over time?

Post-marketing reports indicate that the muscle relaxant component has been associated with the development of tolerance (a diminished response to the drug) as well as dependence and withdrawal, particularly with prolonged use.


Q: What are the official recommendations for stopping Naxodol?

The medication is intended only for short-term treatment. Post-marketing experience has reported withdrawal symptoms following abrupt cessation after prolonged use. The management of cessation, particularly after prolonged use, is a matter for consultation with a healthcare provider.


Q: Can Naxodol be used by the elderly or senior citizens?

Patients aged 65 and older are at a greater risk for serious cardiovascular and gastrointestinal adverse events from the NSAID component. Regulatory guidance recommends using the lowest effective dose in this population, and the safety and efficacy of the muscle relaxant component are not established in this age group.


Q: What is the evidence regarding Naxodol use in children or adolescents?

Safety and effectiveness have not been established for use in pediatric patients under 16 years of age based on official regulatory data. Therefore, the use of the medication in this population is generally not recommended.


Q: Can Naxodol be taken with supplements or herbal remedies?

Caution is necessary as the Carisoprodol component interacts with certain enzymes, and the herbal product St. John's Wort is specifically mentioned as a potential interacting agent. The determination of whether to use supplements or herbal remedies alongside this medication requires evaluation by a healthcare professional.

Advertisements

How should Naxodol (NSAID) be stored and disposed of?

Storage Requirements

Naxodol (Naproxen/Carisoprodol) must be stored at Controlled Room Temperature, specifically between 20 to 25 C (68 to 77 F). Temperature excursions are permitted between 15 and 30 C.

The medication must be protected from light and high humidity, and should avoid excessive heat above 40 C. Store the product in a well-closed, light-resistant container, as specified in regulatory labeling.

Handling and Disposal

For child safety, the medicine must be kept out of the reach of children. Regarding disposal, patients should consult a pharmacist or local waste disposal service for guidance on unused or expired product and must not flush the medicine down a toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Naxodol (NSAID) found in:

A-Z Index: